[FinancialReports](/) / [Companies](/companies/search/) / [India](/companies/countries/india/) / **RDY** ![DR REDDYS LABORATORIES LTD logo](https://cdn.financialreports.eu/financialreports/media/DR%20REDDYS%20LABORATORIES%20LTD/other/DR_REDDYS_LABORATORIES_LTD-logo.png) # DR REDDYS LABORATORIES LTD — Investor Relations & Filings Ticker · **RDY** ISIN · **US2561352038** LEI · **335800OVDPY3DVZR2798** BSE.NS Manufacturing [Open in API](/api-solutions/) Overview Filings 2345 Market data Peer group API Filings indexed 2,345 across all filing types Latest filing 2026-06-15 Regulatory Filings Country IN India Listing BSE.NS RDY ## About DR REDDYS LABORATORIES LTD Dr. Reddy's Laboratories Ltd. is an integrated global pharmaceutical company focused on providing affordable and innovative medicines. The company's core activities include the development, manufacturing, and marketing of a broad portfolio of products. This portfolio encompasses Active Pharmaceutical Ingredients (APIs), generic and branded-generic formulations, over-the-counter (OTC) products, and biologics. In addition to its significant presence in the generics market, the company invests in the research and development of novel molecules and proprietary products, with a focus on therapeutic areas such as dermatology and neurology. Dr. Reddy's is also committed to sustainable operations, actively working to reduce its environmental footprint through initiatives in water conservation, waste reduction, and decarbonisation. ## Recent filings View all 2345 → | Filing | Released | Lang | Actions | | --- | --- | --- | --- | | [**FORM 6-K**](/filings/dr-reddys-laboratories-ltd/regulatory-filings/2026/48074118/) Regulatory Filings Classification · 95% confidence The document is a Form 6-K filing, which is a report of a foreign private issuer under SEC rules, typically used by foreign companies to furnish interim information. The document is only 2,617 characters long, indicating it is a relatively brief submission. The content indicates it is an SEC filing under the Exchange Act, providing an 'Intimation dated June 13, 2026' as an exhibit. The text does not contain comprehensive financial statements or detailed analysis but rather seems to provide an update or notification. It is not an annual report (10-K), interim report (IR), or earnings release (ER). Instead, it aligns with a typical regulatory filing used for updates or miscellaneous reports not fitting other categories. Thus, the appropriate classification is a Regulatory Filing (RNS), the fallback category for such documents. | 2026-06-15 | English | | | [**Press Release**](/filings/dr-reddys-laboratories-ltd/regulatory-filings/2026/48066206/) Regulatory Filings Classification · 95% confidence The document is a press release announcing the launch of a pharmaceutical product (Bosutinib Tablets 400mg) by Dr. Reddy's Laboratories. It is addressed to stock exchanges under regulatory disclosure rules and contains no financial performance data, no financial statements, or management discussion. It is a regulatory disclosure of a material event (product launch) rather than a financial report or detailed corporate filing. It is not an Annual Report, Interim Report, Earnings Release, nor a Management Discussion or M&A or Governance or Remuneration document. It fits the category of a general Regulatory Filing (RNS) as it discloses material information per listing obligations but is not itself a financial report or meeting-related document. Confidence is high due to the clear nature and content of the filing as a material event announcement under Regulation 30 of SEBI Listing Obligations. | 2026-06-13 | English | | | [**Press Release - Launch of Bosutinib Tablets 400mg.**](/filings/dr-reddys-laboratories-ltd/regulatory-filings/2026/48066227/) Regulatory Filings Classification · 95% confidence The document is a press release announcing the first-to-market launch of a pharmaceutical product, Bosutinib Tablets 400mg, in the United States by Dr. Reddy's Laboratories. It includes detailed marketing and product launch information, regulatory references (SEBI Regulations), but does not contain any financial statements, comprehensive financial performance, or management discussion and analysis. It is neither an earnings release nor an annual or interim financial report; instead, it is a disclosure to the stock exchanges about a commercial event. The document is not an announcement about a report but itself the disclosure of a significant event relating to product launch and business activity. Therefore, it fits best under Regulatory Filings (RNS), which encompasses miscellaneous regulatory announcements and disclosures that don't fall under more specific categories. | 2026-06-13 | English | | | [**Copies of newspaper publication**](/filings/dr-reddys-laboratories-ltd/regulatory-filings/2026/48061594/) Regulatory Filings Classification · 95% confidence The document is a letter from Dr. Reddy's Laboratories addressed to the National Stock Exchange of India and BSE Limited, enclosing copies of a newspaper advertisement published regarding the opening of a special window for physical share transfer re-lodgment. The document references Regulation 47 of SEBI listing obligations, which pertains to compliance through advertisement publications. There are no financial statements, management commentary, comprehensive financial data, or meeting minutes. The length is just over 5,000 characters, but the content is essentially an official announcement about a newspaper advertisement related to compliance rather than a report or detailed filing. Therefore, it falls under Regulatory Filings (RNS) as a general announcement that does not fit into the other more specific categories. The presence of regulatory references and the nature of the communication support this classification. | 2026-06-12 | English | | | [**Copy of Newspaper Publication**](https://cdn.financialreports.eu/financialreports/media/filings/30528/2026/RNS/30528_rns_2026-06-12_d505a5cb-d80e-44b7-bee6-f6222cf2feb1.pdf) Regulatory Filings | 2026-06-12 | English | | | [**Disclosure under SEBI Takeover Regulations**](/filings/dr-reddys-laboratories-ltd/regulatory-filings/2026/48055012/) Regulatory Filings Classification · 75% confidence The document is a formal disclosure submitted to stock exchanges under SEBI’s (Substantial Acquisition of Shares and Takeover) Regulations regarding no encumbrance created by the promoter group. It does not report financial results, management changes, voting outcomes, or detailed financial statements. It is a regulatory compliance filing that does not fit other specific categories, making it a fallback “Regulatory Filings.” | 2026-06-12 | English | | ## Browse filings by year 17 years - [2026 142 filings](/companies/dr-reddys-laboratories-ltd/2026/) - [2025 283 filings](/companies/dr-reddys-laboratories-ltd/2025/) - [2024 402 filings](/companies/dr-reddys-laboratories-ltd/2024/) - [2023 273 filings](/companies/dr-reddys-laboratories-ltd/2023/) - [2022 261 filings](/companies/dr-reddys-laboratories-ltd/2022/) - [2021 208 filings](/companies/dr-reddys-laboratories-ltd/2021/) - [2020 249 filings](/companies/dr-reddys-laboratories-ltd/2020/) - [2019 235 filings](/companies/dr-reddys-laboratories-ltd/2019/) - [2018 77 filings](/companies/dr-reddys-laboratories-ltd/2018/) - [2017 54 filings](/companies/dr-reddys-laboratories-ltd/2017/) - [2016 42 filings](/companies/dr-reddys-laboratories-ltd/2016/) - [2015 23 filings](/companies/dr-reddys-laboratories-ltd/2015/) - [2014 20 filings](/companies/dr-reddys-laboratories-ltd/2014/) - [2013 25 filings](/companies/dr-reddys-laboratories-ltd/2013/) - [2012 18 filings](/companies/dr-reddys-laboratories-ltd/2012/) - [2011 16 filings](/companies/dr-reddys-laboratories-ltd/2011/) - [2010 17 filings](/companies/dr-reddys-laboratories-ltd/2010/) [["13", "AGM Information"], ["1", "Annual Report"], ["53", "Audit Report / Information"], ["47", "Board/Management Information"], ["7", "Call Transcript"], ["48", "Capital/Financing Update"], ["22", "Declaration of Voting Results & Voting Rights Announcements"], ["20", "Director's Dealing"], ["6", "Earnings Release"], ["10", "Environmental & Social Information"], ["11", "Governance Information"], ["19", "Interim / Quarterly Report"], ["12", "Investor Presentation"], ["30", "Legal Proceedings Report"], ["23", "M&A Activity"], ["24", "Major Shareholding Notification"], ["46", "Proxy Solicitation & Information Statement"], ["18", "Regulatory Filings"], ["9", "Remuneration Information"], ["42", "Report Publication Announcement"], ["51", "Share Issue/Capital Change"], ["52", "Transaction in Own Shares"]] [["1", "English"]] Financial Reporting & Info Annual General Meeting Debt Information ESG Information Equity Information Investor Communication M&A, Partnerships & Legal Management & Remuneration Other Filing type Language Start date End date Apply filters [Clear](/companies/dr-reddys-laboratories-ltd/) Report missing filing Download originals Download Markdown | | ID | Filing | Released | Lang | Actions | | --- | --- | --- | --- | --- | --- | | [2026](/companies/dr-reddys-laboratories-ltd/2026/) 15 filings | | | | | | | | 48074118 | [**FORM 6-K**](/filings/dr-reddys-laboratories-ltd/regulatory-filings/2026/48074118/) Regulatory Filings Classification · 95% confidence The document is a Form 6-K filing, which is a report of a foreign private issuer under SEC rules, typically used by foreign companies to furnish interim information. The document is only 2,617 characters long, indicating it is a relatively brief submission. The content indicates it is an SEC filing under the Exchange Act, providing an 'Intimation dated June 13, 2026' as an exhibit. The text does not contain comprehensive financial statements or detailed analysis but rather seems to provide an update or notification. It is not an annual report (10-K), interim report (IR), or earnings release (ER). Instead, it aligns with a typical regulatory filing used for updates or miscellaneous reports not fitting other categories. Thus, the appropriate classification is a Regulatory Filing (RNS), the fallback category for such documents. | 2026-06-15 | English | | | | 48066206 | [**Press Release**](/filings/dr-reddys-laboratories-ltd/regulatory-filings/2026/48066206/) Regulatory Filings Classification · 95% confidence The document is a press release announcing the launch of a pharmaceutical product (Bosutinib Tablets 400mg) by Dr. Reddy's Laboratories. It is addressed to stock exchanges under regulatory disclosure rules and contains no financial performance data, no financial statements, or management discussion. It is a regulatory disclosure of a material event (product launch) rather than a financial report or detailed corporate filing. It is not an Annual Report, Interim Report, Earnings Release, nor a Management Discussion or M&A or Governance or Remuneration document. It fits the category of a general Regulatory Filing (RNS) as it discloses material information per listing obligations but is not itself a financial report or meeting-related document. Confidence is high due to the clear nature and content of the filing as a material event announcement under Regulation 30 of SEBI Listing Obligations. | 2026-06-13 | English | | | | 48066227 | [**Press Release - Launch of Bosutinib Tablets 400mg.**](/filings/dr-reddys-laboratories-ltd/regulatory-filings/2026/48066227/) Regulatory Filings Classification · 95% confidence The document is a press release announcing the first-to-market launch of a pharmaceutical product, Bosutinib Tablets 400mg, in the United States by Dr. Reddy's Laboratories. It includes detailed marketing and product launch information, regulatory references (SEBI Regulations), but does not contain any financial statements, comprehensive financial performance, or management discussion and analysis. It is neither an earnings release nor an annual or interim financial report; instead, it is a disclosure to the stock exchanges about a commercial event. The document is not an announcement about a report but itself the disclosure of a significant event relating to product launch and business activity. Therefore, it fits best under Regulatory Filings (RNS), which encompasses miscellaneous regulatory announcements and disclosures that don't fall under more specific categories. | 2026-06-13 | English | | | | 48061594 | [**Copies of newspaper publication**](/filings/dr-reddys-laboratories-ltd/regulatory-filings/2026/48061594/) Regulatory Filings Classification · 95% confidence The document is a letter from Dr. Reddy's Laboratories addressed to the National Stock Exchange of India and BSE Limited, enclosing copies of a newspaper advertisement published regarding the opening of a special window for physical share transfer re-lodgment. The document references Regulation 47 of SEBI listing obligations, which pertains to compliance through advertisement publications. There are no financial statements, management commentary, comprehensive financial data, or meeting minutes. The length is just over 5,000 characters, but the content is essentially an official announcement about a newspaper advertisement related to compliance rather than a report or detailed filing. Therefore, it falls under Regulatory Filings (RNS) as a general announcement that does not fit into the other more specific categories. The presence of regulatory references and the nature of the communication support this classification. | 2026-06-12 | English | | | | 48057208 | [**Copy of Newspaper Publication**](https://cdn.financialreports.eu/financialreports/media/filings/30528/2026/RNS/30528_rns_2026-06-12_d505a5cb-d80e-44b7-bee6-f6222cf2feb1.pdf) Regulatory Filings | 2026-06-12 | English | | | | 48055012 | [**Disclosure under SEBI Takeover Regulations**](/filings/dr-reddys-laboratories-ltd/regulatory-filings/2026/48055012/) Regulatory Filings Classification · 75% confidence The document is a formal disclosure submitted to stock exchanges under SEBI’s (Substantial Acquisition of Shares and Takeover) Regulations regarding no encumbrance created by the promoter group. It does not report financial results, management changes, voting outcomes, or detailed financial statements. It is a regulatory compliance filing that does not fit other specific categories, making it a fallback “Regulatory Filings.” | 2026-06-12 | English | | | | 48030318 | [**FORM 6-K**](/filings/dr-reddys-laboratories-ltd/regulatory-filings/2026/48030318/) Regulatory Filings Classification · 90% confidence The document is a SEC Form 6-K cover page for a foreign private issuer (Dr. Reddy’s Laboratories), reporting an “Intimation dated June 10, 2026.” It contains only the 6-K boilerplate, signature, and exhibit reference, with no substantive financial data or event details. As it functions as a general regulatory submission wrapper rather than an actual report (e.g., financial statements, earnings, or capital action announcement), it falls under the catch-all category for miscellaneous regulatory filings. Therefore, the appropriate classification is Regulatory Filings (RNS). | 2026-06-10 | English | | | | 48025992 | [**Intimation of analyst meet**](/filings/dr-reddys-laboratories-ltd/regulatory-filings/2026/48025992/) Regulatory Filings Classification · 92% confidence The document is a brief disclosure letter under Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, informing stock exchanges of the schedule of analyst/institutional investor meetings. It contains no financial statements, earnings data, or other substantive report content, nor does it fit any specialized category (e.g., M&A, dividends, share issuances). It is a routine regulatory notice, so it falls under the general “Regulatory Filings” category (RNS). | 2026-06-10 | English | | | | 48025921 | [**Analysts/Institutional Investor Meet/Con. Call Updates**](/filings/dr-reddys-laboratories-ltd/regulatory-filings/2026/48025921/) Regulatory Filings Classification · 80% confidence The document is a brief stock exchange filing under SEBI LODR Listing Regulation 30, providing the schedule of analyst/institutional investor meetings. It does not contain financial results or substantive data, nor is it a proxy or AGM material. It is a regulatory market disclosure, fitting the Regulatory Filings (RNS) category. | 2026-06-10 | English | | | | 47982031 | [**FORM 6-K**](/filings/dr-reddys-laboratories-ltd/regulatory-filings/2026/47982031/) Regulatory Filings Classification · 97% confidence The document is a U.S. SEC Form 6-K “Report of Foreign Private Issuer Pursuant to Rule 13A-16 or 15D-16” filed by Dr. Reddy’s Laboratories. Form 6-K is a regular compliance/regulatory filing by foreign private issuers to furnish material information but does not itself constitute an annual or interim financial report. It does not present detailed financial statements or earnings data, nor is it announcing a separate report’s publication. Therefore, it falls under the general regulatory filing category (RNS). | 2026-06-05 | English | | | | 47978314 | [**General Updates**](/filings/dr-reddys-laboratories-ltd/share-issuecapital-change/2026/47978314/) Share Issue/Capital Change Classification · 95% confidence The document is a regulatory disclosure under SEBI Listing Regulations informing stock exchanges of the allotment of new equity shares on exercise of employee stock options. It provides all details of the issuance (number of shares, ISIN, par value, etc.). This is an announcement of a new share issue/capital change rather than a full report or other type of filing. Therefore, it falls under Share Issue/Capital Change (SHA). | 2026-06-05 | English | | | | 47978439 | [**Allotment of Employee Stock Options**](/filings/dr-reddys-laboratories-ltd/share-issuecapital-change/2026/47978439/) Share Issue/Capital Change Classification · 90% confidence The document is a regulatory disclosure made under SEBI Listing Regulations (Regulation 30) announcing the allotment of 12,100 new equity shares on exercise of employee stock options. It provides detailed share issue parameters (scheme name, number of shares, par value, ISIN, share certificate numbers, total issued capital post-issue). This constitutes a share issuance/capital change announcement rather than a full financial report or other category. Therefore, it is classified as a Share Issue/Capital Change (SHA). | 2026-06-05 | English | | | | 47944335 | [**Intimation of Analyst/Investor meet**](/filings/dr-reddys-laboratories-ltd/regulatory-filings/2026/47944335/) Regulatory Filings Classification · 75% confidence The document is a brief SEBI Regulation 30 disclosure notifying stock exchanges of upcoming analyst and institutional investor meetings. It does not contain financial results, shareholding changes, proxy materials, or a full report. It is a general regulatory announcement/fallback category, so it fits Regulatory Filings (RNS). | 2026-06-03 | English | | | | 47944702 | [**Analysts/Institutional Investor Meet/Con. Call Updates**](/filings/dr-reddys-laboratories-ltd/regulatory-filings/2026/47944702/) Regulatory Filings Classification · 65% confidence The document is an intimation under Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015. It is a compliance/regulatory announcement disclosing the schedule of analyst/investor meetings, rather than an actual financial report, presentation, or detailed results. Thus, it falls under general regulatory filings. | 2026-06-03 | English | | | | 47946952 | [**FORM 6-K**](/filings/dr-reddys-laboratories-ltd/regulatory-filings/2026/47946952/) Regulatory Filings Classification · 90% confidence The document is a Form 6-K filed by a foreign private issuer (Dr. Reddy’s Laboratories) pursuant to the SEC’s Exchange Act rules. It contains the cover page and exhibit list (intimation dated June 3, 2026) but no substantive financial statements or narrative. This is a routine regulatory filing, not an annual or quarterly report, earnings release, management discussion, or other specific category. Therefore it falls under the general regulatory filing category (RNS). | 2026-06-03 | English | | Page **1** of **157** 1 [2](?page=2#filings) [3](?page=3#filings) … [Next](?page=2#filings) ## Market data ### Market data not available Last price Market cap volume Day range today 52-week range trailing ### Price history 1Y 5Y 10Y ## Peer group · Manufacture of pharmaceuticals, medicinal chemical and botanical products 2,202 peers | Company | Ticker | Country | Sector | | --- | --- | --- | --- | | [**13260917 Canada Inc.**](/companies/13260917-canada-inc/) Biotech developing oral small molecules to restore muscle s… | MSCL | CA | Manufacturing | | [**1608557 Ontario Inc.**](/companies/1608557-ontario-inc/) Biopharmaceutical company dedicated to R&D, discovery, and … | OTROQ | CA | Manufacturing | | [**3B BlackBio Dx Limited**](/companies/3b-blackbio-dx-limited/) Develops molecular diagnostic kits for oncology, infectious… | 3BBLACKBIO | IN | Manufacturing | | [**3D Medicines Inc.**](/companies/3d-medicines-inc/) Commercial-stage biopharma specializing in next-generation … | 1244 | HK | Manufacturing | | [**3SBio Inc.**](/companies/3sbio-inc/) Biopharmaceutical enterprise specializing in R&D, productio… | 1530 | KY | Manufacturing | | [**4BASEBIO PLC**](/companies/4basebio-plc/) Manufactures GMP-grade synthetic DNA for next-generation th… | 4BB | GB | Manufacturing | | [**4D Molecular Therapeutics, Inc.**](/companies/4d-molecular-therapeutics-inc/) Develops genetic medicines using AAV vectors for ophthalmol… | FDMT | US | Manufacturing | | [**4Front Ventures Corp.**](/companies/4front-ventures-corp/) Vertically integrated cannabis operator managing cultivatio… | FFNT | CA | Manufacturing | | [**4SC AG**](/companies/4sc-ag/) Biopharmaceutical company with no products under developmen… | VSC | DE | Manufacturing | | [**60 DEGREES PHARMACEUTICALS, INC.**](/companies/60-degrees-pharmaceuticals-inc/) Develops and commercializes medicines for infectious diseas… | SXTP | US | Manufacturing | Page **1** of **221** 1 [2](?peer_page=2#peers) [3](?peer_page=3#peers) … [Next](?peer_page=2#peers) ### DR REDDYS LABORATORIES LTD via the API Pull this company's filings, identifiers, and metadata as JSON or Markdown. Authenticate with your API key, then query by company ID, ISIN, or LEI. Full schema documented in the OpenAPI spec. [Get API access](/api-solutions/) [Read API reference](/developers/reference/) Base URLapi.financialreports.eu Auth headerx-api-key Company ID30528 TickerRDY ISINUS2561352038 ### Endpoints most-used routes for this company | | | | | --- | --- | --- | | GET | /api/companies/30528/ | Company identity, sector, listing, identifiers | | GET | /api/filings/?company=30528 | Paginated list of all filings (filterable by type, date, language) | | GET | /api/filings/{id}/ | Single filing — metadata, document URL, processing status | | GET | /api/filings/{id}/markdown/ | Filing content as Markdown (PDF → text/tables/figures) | | GET | /api/isins/?company=30528 | All ISINs registered to this company | | GET | /api/filing-types/ | Reference: every filing-type code + category | Full reference: [API reference](/developers/reference/) · [OpenAPI schema](/api/schema/) ### cURL latest filings for DR REDDYS LABORATORIES LTD ``` $ curl https://api.financialreports.eu/api/filings/?company=30528 \ -H "x-api-key: $FR_API_KEY" \ -H "Accept: application/json" ``` ### Python requests ``` import requests r = requests.get( "https://api.financialreports.eu/api/filings/", params={"company": 30528}, headers={"x-api-key": API_KEY}, ) filings = r.json()["results"] ``` ### MCP server Claude · Claude Code · ChatGPT [Claude setup →](/integrations/claude/) [ChatGPT setup →](/integrations/chatgpt/) [Claude Code setup →](/integrations/claude-code/) ``` // MCP server URL https://mcp.financialfilings.com/mcp // Once connected, the LLM can query this company directly: "Pull the latest 5 filings for DR REDDYS LABORATORIES LTD (id: 30528)" ``` #### AI · Markdown Filings as Markdown Drop the latest filing into Claude or ChatGPT, or query via MCP from your client. [Open Markdown↗](/filings/dr-reddys-laboratories-ltd/regulatory-filings/2026/48074118/) [Open in MCP↗](/integrations/claude/) [cURL endpoint$](/api-solutions/) #### Identity Legal nameDR REDDYS LABORATORIES LTD HQHYDERABAD, IN ListingBSE.NS ISINUS2561352038 [+4](/companies/dr-reddys-laboratories-ltd/securities/) LEI335800OVDPY3DVZR2798 Sector[Manufacturing](/companies/sectors/manufacturing/) Industry[Manufacture of pharmaceuticals, medicinal chemical and botanical products](/companies/sectors/manufacturing/manufacture-of-pharmaceuticals-medicinal-chemical-and-botanical-products/) #### Coverage Filings indexed 2,345 Next annual report Jun 10–Jul 8, 2027 Confidence 69% ### Report missing filing Can't find a specific document? Let us know and we'll add it within 24 hours. What is missing or wrong? Your email We will notify you once the filing is added. Cancel Send report Sending… Report sent Thank you. We will check the data and update it shortly. × (function() { const tabs = document.querySelectorAll('.cmp-tabs-wrap .fr-tab'); const panes = document.querySelectorAll('.tab-pane'); function activate(target, pushHash) { tabs.forEach(t => { const isActive = t.dataset.tab === target; t.classList.toggle('fr-tab--active', isActive); t.setAttribute('aria-selected', isActive ? 'true' : 'false'); }); panes.forEach(p => { const isActive = p.dataset.pane === target; p.classList.toggle('tab-pane--active', isActive); p.hidden = !isActive; }); if (pushHash) { try { history.replaceState(null, '', '#' + target); } catch (e) {} } } tabs.forEach(tab => { tab.addEventListener('click', () => { activate(tab.dataset.tab, true); window.scrollTo({ top: 0, behavior: 'instant' }); }); }); const initial = (window.location.hash || '').replace('#', ''); const validTabs = ['overview', 'filings', 'financials', 'market', 'peers', 'api']; const legacyMap = { 'market-data': 'market', 'peer-group': 'peers' }; let target = legacyMap[initial] || (validTabs.indexOf(initial) >= 0 ? initial : 'overview'); if (target !== 'overview') activate(target, false); })();